Company news
Shanghai Pharmaceuticals Holding Co. Ltd. Class A (SSE:601607) news
Shanghai Pharmaceuticals Holding Co. Ltd. Class A news releases on 6ix. Latest, Dec 9, 2025: Announcement on Amisulpride Orodispersible Tablets Passing…
Press releases — page 2
Announcement on Amisulpride Orodispersible Tablets Passing the National Medical Insurance Negotiation and Being Successfully Included in the National Medical Insurance Catalog
December 8, 2025
Announcement on the Termination of the Cooperation Agreement with Guizhou Shenuo Biotechnology Co., Ltd.
December 5, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
November 28, 2025
上海医药集团股份有限公司关于召开2025年第二次临时股东大会的通知
November 18, 2025
Announcement on Approval of Eslicarbazepine Acetate Tablets by the U.S. FDA
November 10, 2025
Announcement on Obtaining Approval for Production of Tofacitinib Citrate Sustained-Release Tablets
November 6, 2025
Announcement on Resolutions of the 25th Meeting of the 8th Board of Directors
October 30, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 28, 2025
Announcement on the Subsidiary Becoming the Marketing Authorization Holder of Amisulpride Orally Disintegrating Tablets
October 24, 2025
Announcement on Obtainment of U.S. FDA Approval for Doxycycline Capsules
October 14, 2025
Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan and in Q3 2025
October 9, 2025
Announcement on Resignation of Senior Management Members
September 25, 2025
Indicative Announcement on Changes in Shareholder's Equity
September 22, 2025
Announcement on Nicorandil Tablet Passing Generic Drug Consistency Evaluation
September 18, 2025
Announcement on Shareholding Increase Plan for the Controlling Shareholder
September 15, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Aripiprazole Tablets
September 12, 2025
Announcement on Diprophylline Injection Passing Generic Drug Consistency Evaluation
September 4, 2025
Announcement on Verapamil Hydrochloride Injection Passing Generic Drug Consistency Evaluation
September 1, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Oxytocin Injection and Octreotide Acetate Injection
August 22, 2025
Announcement on the Receipt of Clinical Trial Approval Notice for a New Indication of B019
July 29, 2025
Announcement on Salbutamol Sulfate Injection Passing Generic Drug Consistency Evaluation
July 28, 2025
Announcement on Acquisition of 10% Equity of SIIC Finance Co., Ltd. and Related Party Transactions
July 25, 2025
Shanghai Pharmaceuticals : The Fortune 500 company Shanghai Pharmaceuticals enters the dental equipment market by acquiring Finnish dental equipment company Fimet Oy and its operations in Finland and China
July 6, 2021
Shanghai Pharmaceuticals : CONNECTED TRANSACTION PROPOSED NON-PUBLIC ISSUANCE OF A SHARES
May 12, 2021
Shanghai Pharmaceuticals : SUPPLEMENT ANNOUNCEMENT TO THE 2019 SHARE OPTION INCENTIVE SCHEME OF THE COMPANY
August 21, 2020
Shanghai Pharmaceuticals : GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME
December 19, 2019
Shanghai Pharmaceuticals : RESULTS OF THE EXTRAORDINARY GENERAL MEETING, A SHARE CLASS MEETING, AND H SHARE CLASS MEETING
December 18, 2019
Shanghai Pharmaceuticals : Proposed Adoption of the 2019 Share Option Scheme Assessment Management Measures for the Implementation of the 2019 Share Option Scheme and Proposed Authorization to the Board to Deal with Relevant Matters in Relation to the 2019 Share Option Scheme
October 31, 2019
Shanghai Pharmaceuticals : PROPOSED ADOPTION OF THE SHARE OPTION SCHEME AND THE GRANT THEREUNDER
September 30, 2019
Shanghai Pharmaceuticals : CSRC'S APPROVAL ON ISSUANCE OF NEW H SHARES
September 20, 2019
Shanghai Pharmaceuticals : CHANGE OF BOARD SECRETARY, JOINT COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE
August 29, 2019